Biotech | March 01, 2022
South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Key takeaways of Q3FY22 quarter & conference call highlights
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Subscribe To Our Newsletter & Stay Updated
